CLL

After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as well as survivorship news.

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.

After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient.

Fifteen years after being diagnosed with small lymphocytic lymphoma, I’ve found healing and meaning in the work I love and the life I’m grateful to live.

I’m a single mom with chronic lymphocytic leukemia sharing how cancer tested me but revealed my resilience, hardship and the power of speaking up.

As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.

Teddy bears offer emotional comfort and connection for adults with cancer, easing anxiety and fostering trust during treatment.

As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop my treatment. Life is a gift.

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found.

After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.

Each spring, I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination.

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and patience.

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found to be beneficial.

When my spouse and I both faced cancer, maintaining a positive attitude, seeking support, listening empathetically and managing stress helped us through it.

Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis diagnosis.

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Waiting for results of a CT scan after a cancer diagnosis is agonizing, as I anxiously await news on whether my disease has returned.

At my routine oncology checkup, I regretted not bringing my husband when an unexpected medication changes left me feeling overwhelmed and alone.

When I recognize my frustration and dissapointment with the test results for my chronic lymphocytic leukemia, I find comfort in listening to music.

As I prepare for treatment of my chronic lymphocytic leukemia, I reflect on the challenges of aging and side effects while staying focused on living fully.

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.